Abigail Brooks is an assistant editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Eli Lilly and Company has announced data from the phase 3 LUCENT-3 open-label extension study establishing mirikizumab-mrkz (Omvoh) as the first and only interleukin-23p19 (IL-23p19) to help patients with moderately to severely active ulcerative colitis (UC) achieve sustained, long-term outcomes through 4 years.

According to an October 7, 2025, press release from the Company, the results were seen across multiple symptomatic, clinical, endoscopic, histologic and quality-of-life measures, including among patients who had previously failed a biologic or advanced therapy (27%). The data represent the final results from the LUCENT-3 phase 3 open-label extension study and were presented at United European Gastroenterology (UEG) Week in Berlin.

"Helping people with ulcerative colitis achieve long-term comprehensive disease control is a major goal for gastroenterologists, as it has remained out of reach for many patients," Bruce Sands, MD, MS, Dr. Burrill B. Crohn Professor of Medicine and Chief of the Dr. Henry D. Janowitz Division of Gastroenterology at Icahn School of Medicine at Mount Sinai, said in a statement.

 "These long-term findings reinforce mirikizumab as a highly effective biologic for UC management, showing sustained clinical, endoscopic and steroid-free remission over four years, and improvement in bowel urgency, which can present a significant burden on patients' lives."

In January 2025, the interleukin-23p19 antagonist earned FDA approval for the treatment of adults with moderately to severely active Crohn's disease (CD), expanding upon its previous indication for UC in 2023. Mirikizumab’s approval for CD was based on positive results from the phase 3 VIVID-1 study in adults with moderately to severely active CD who had an inadequate response, loss of response, or intolerance to corticosteroids, immunomodulators, and/or biologics.

Mirikizumab’s use in UC was studied in 2 phase 3 randomized, double-blind and placebo controlled clinical trials that evaluated the efficacy and safety of mirikizumab in adults with moderately to severely active UC and included patients who had never tried a biologic and harder-to-treat patients who had previously taken a biologic that failed. LUCENT-3, the single-arm long-term phase 3 open-label extension of LUCENT-1 and LUCENT-2, evaluated the efficacy and safety of mirikizumab in patients with UC for an additional 3 years of treatment, up to 4 years total.

As described in the release from Eli Lilly and Company, in LUCENT-3, the following results were observed after 4 years of total treatment among those who achieved clinical remission with mirikizumab at 1 year in the phase 3 LUCENT-2 study:

78% achieved corticosteroid-free clinical remission

78% sustained long-term clinical remission

81% sustained endoscopic remission, defined as an endoscopic subscore of 0 or 1 (excluding friability)

90% achieved remission on the Inflammatory Bowel Disease Questionnaire

66% achieved histological-endoscopic mucosal improvement, an important marker of deep inflammation resolution

93% achieved a 3 or more-point reduction on the Urgency Numeric Rating Scale (UNRS), and 74% achieved UNRS = 0 or 1

Investigators noted the long-term safety profile in patients with moderately to severely active UC was consistent with the known safety profile of mirikizumab, with no new safety signals observed. Of patients who completed 1 year of blinded mirikizumab maintenance therapy in LUCENT-2 and continued on to LUCENT-3, 12% reported a serious adverse event, while 7% discontinued treatment due to an adverse event.

"With these results, [mirikizumab] continues to set a high standard as the first and only IL-23p19 with evidence of sustained efficacy and consistent safety in ulcerative colitis over four years," Mark Genovese, MD, senior vice president of Lilly Immunology development, said in a statement.

As described by Eli Lilly and Company, the Company is advancing combination studies of mirikizumab aimed at delivering breakthrough induction efficacy while maintaining long-term remission and safety, including studies with eltrekibart, a monoclonal antibody that targets neutrophil-driven inflammation, and with LY4268989 (MORF-057), an oral α4β7 integrin inhibitor. Lilly is also exploring the potential of incretins in immunology and has initiated the COMMIT-UC and COMMIT-CD trials evaluating the concomitant use of mirikizumab with an incretin-based therapy.

Eli Lilly and Company. Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis. October 7, 2025. Accessed October 7, 2025. 

https://investor.lilly.com/news-releases/news-release-details/lillys-omvoh-mirikizumab-mrkz-first-and-only-il-23p19-antagonist

Brooks A. FDA Approves Mirikizumab (Omvoh) for Crohn’s Disease. HCPLive. January 15, 2025. Accessed October 7, 2025. 

https://www.hcplive.com/view/fda-approves-mirikizumab-omvoh-for-crohn-disease

Articles

Eli Lilly's phase 3 LUCENT-3 study highlights mirikizumab (Omvoh) as the first IL-23p19 antagonist to achieve sustained, long-term outcomes in ulcerative colitis (UC) over four years. The study demonstrated significant improvements across clinical, endoscopic, and quality-of-life measures, even in patients who previously failed biologic therapies. Mirikizumab also received FDA approval for Crohn's disease based on the VIVID-1 study. The safety profile remained consistent, with no new safety signals. Eli Lilly is advancing combination studies to enhance induction efficacy and maintain long-term remission in UC and Crohn's disease.

LUCENT-3 open-label extension study data establish mirikizumab-mrkz (Omvoh) as the first and only IL-23p19 to show sustained long-term outcomes in UC through 4 years.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Ulcerative Colitis

Ulcerative Colitis condition center page, resources on the topics of medical news and expert insight into colitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on UC research, treatment, and drug development.

LUCENT-3: Mirikizumab (Omvoh) Shows Sustained Benefit in Ulcerative Colitis Through 4 Years

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

The third quarter of 2025 saw a series of revolutionary changes in cardiology, with major regulatory updates, significant new trail data, and the release of new guidelines in 

 approved bumetanide nasal spray for congestive HF, which represents an entirely new uptake pathway for cardiovascular medication, and finerenone for HF with preserved ejection fraction (HFpEF) ≥40%, filling a critical need in a growing at-risk population.

Q3 also saw major advancements in the cardiology pipeline, with the achievement of primary endpoints for both baxdrostat and mavacamten. Even the failed VICTOR trial of vericiguat brought about meaningful updates, indicating the drug’s efficacy in reducing cardiovascular mortality, all-cause mortality, sudden cardiac death, and HF-related death.

 has collected some of the most impactful headlines from Q3 of 2025 – check them out below:

FDA Approves Bumetanide Nasal Spray for Edema with Congestive Heart Failure

On September 15, 2025, the FDA opened an unexplored pathway for cardiovascular disease treatment with their approval of bumetanide nasal spray. Designed to reduce edema in patients with congestive HF, liver disease, and 

, this spray is the first intranasal loop diuretic in cardiology and could potentially enable earlier – and possibly outpatient – intervention in HF treatment.

FDA Approves Finerenone (Kerendia) for Heart Failure with Ejection Fraction of 40% or More

On July 14, 2025, finerenone became a major factor for HFpEF care alongside SGLT2 inhibitors, indicated for reducing the risk of cardiovascular death, HF hospitalization, and urgent HF visits for adults with heart failure with mildly reduced ejection fraction (HFmrEF) and HFpEF. The FDA approval significantly expanded treatment options for HF patients with a left ventricular ejection fraction ≥40%, which is a consistently growing and significantly at-risk population.

AHA & ACC Release New Guidelines for High Blood Pressure to Reduce CVD Risk

In August 2025, the American Heart Association and the American College of Cardiology released a joint guideline to encourage physical activity, heart-healthy diets, and stress management for the reduction of hypertension. Given the condition’s prevalence in diseases across various specialties, including kidney disease, 

, and HF, the new guidelines aim to support clinicians at every level in consistently and accurately monitoring their patients’ blood pressure.

ACC/AHA Hypertension Guideline Update: Recommendations for Managing Blood Pressure

HFSA and ASPC Release Statement on Shifting to Prevention in Heart Failure

Also in August 2025, the Heart Failure Society of America and the American Society for Preventive Cardiology released a joint statement calling for a change in how HF treatment is approached. The statement encourages clinicians to view HF as a preventable condition rather than an inevitable outcome of cardiovascular disease. The authors provide a detailed framework suggesting preventive strategies for all stages of HF, independent of ejection fraction, as well as strategies for patients with established diseases and those with advanced therapies like heart transplants.

HFSA/ASPC Heart Failure Prevention: From Prognosis to Prevention in Heart Failure

Baxdrostat Meets Efficacy Endpoint in Phase 3 Trial for Resistant Hypertension

On July 14, 2025, parent company AstraZeneca announced positive topline results from the BaxHTN trial, showing baxdrostat’s capacity for lowering aldosterone in patients with treatment-resistant hypertension. The oral small molecule was administered once daily to patients in a range of doses, all of which efficaciously inhibited ASI to reduce aldosterone production without impacting cortisol levels.

Bax24: Baxdrostat Achieves Primary Endpoint in Treatment-Resistant Hypertension

Don't Miss a Beat: Vericiguat in Heart Failure and the VICTOR Trial, With Javed Butler, MD

Don't Miss a Beat: The VICTOR Trial

Although the VICTOR trial failed to achieve its primary endpoint, vericiguat did prove itself efficacious in reducing several mortality endpoints. This episode of Don’t Miss a Beat follows cohosts Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, as they sit down with Javed Butler, MD, to review the trial’s results and where future trials can go from here.

Aficamten Outperforms Metoprolol in Obstructive Hypertrophic Cardiomyopathy, With Pablo Garcia-Pavia, MD, PhD

The MAPLE-HCM trial, the results of which were presented at the European Society of Cardiology (ESC) Congress 2025, saw aficamten demonstrate superior clinical and functional benefits compared to metoprolol in symptomatic 

obstructive hypertrophic cardiomyopathy (HCM)

. At the end of the 24-week study period, patients assigned to aficamten saw substantial improvements to left ventricular outflow tract gradients, NT-proBNP levels, and left atrial volume index, among other factors in HCM.

COLLIGO-HCM: Mavacamten (CAMZYOS) Effective in Obstructive HCM With Pankaj Arora, MD

Mavacamten, the first and only cardiac myosin inhibitor to receive FDA approval for adults with class II-III obstructive HCM, proved its safety and efficacy in the COLLIGO-HCM trial by parent company Bristol Myers Squibb. The results challenge the broad application of beta blockers and calcium channel blockers, as it provides patients with continued symptoms and elevated gradients with an alternative method of myosin innovation.

The third quarter of 2025 marked significant advancements in cardiology, including FDA approvals, new guidelines, and trial outcomes. The FDA approved bumetanide nasal spray for congestive heart failure and finerenone for heart failure with preserved ejection fraction, expanding treatment options. New guidelines from AHA and ACC emphasized lifestyle changes for hypertension management, while HFSA and ASPC advocated for preventive heart failure strategies. Key trial results included baxdrostat's efficacy in resistant hypertension and aficamten's superiority over metoprolol in obstructive hypertrophic cardiomyopathy, highlighting ongoing innovation in cardiovascular treatment.

The Q3 recap for cardiology spotlights major FDA decisions, new heart failure and hypertension guidelines, and top trial results and research.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Cardiomyopathy

FDA News

Q3 2025 Recap: Cardiology News and Updates

New research is shedding light on a heightened risk of 

metabolic dysfunction-associated steatotic liver disease (MASLD)

 with high intake of both sugar-sweetened beverages (SSBs) and low- or non-sugar-sweetened beverages (LNSSBs), additionally highlighting an increased risk of liver-related mortality with high LNSSB consumption.

The research, presented at United European Gastroenterology Week 2025, assessed data for > 100,000 UK Biobank participants and found intake of > 330 g per day of both LNSSBs and SSBs were linked to elevated MASLD risk, supporting the limitation of both beverages as part of a comprehensive prevention strategy targeting both liver disease and cardio-renal-metabolic health.

Emerging research suggests intake of sugar and its substitutes is linked to cardiometabolic and kidney diseases. A 2024 analysis of UK Biobank data determined that consumption of >1 serving per day of sugar-sweetened beverages was associated with higher risk of incident chronic kidney disease, with risk unaffected by substituting sugar-sweetened beverages with artificially sweetened beverages.

“SSBs have long been under scrutiny, while their ‘diet’ alternatives are often seen as the healthier choice,” lead study author Lihe Liu, a graduate student in the department of gastroenterology at the First Affiliated Hospital of Soochow University in China, said in a statement.

 “Both, however, are widely consumed and their effects on liver health have not been well understood.”

To address this gap in research, investigators conducted a prospective cohort study of 103,251 UK Biobank participants free of baseline liver disease, assessing the associations between SSB and LNSSB intake and the risk of incident MASLD and liver-related mortality.

They assessed beverage consumption through multiple 24-hour dietary questionnaires. The primary outcome was incident MASLD, and secondary outcomes included liver-related mortality and liver fat content measured by MRI- derived proton density fat fraction.

During a median 10.3-year follow-up, 949 participants developed MASLD and 103 died from liver-related causes. Investigators noted increased intake of LNSSBs, and SSBs, defined as >330 g/day, were associated with elevated MASLD risk (hazard ratio, 1.597 and 1.502, respectively; both 

Further analysis revealed LNSSB consumption increased liver-related mortality risk in a dose-dependent manner. However, no significant association was observed for SSBs.

Investigators noted both beverages were positively associated with liver fat content. Replacing 330 g/day of either beverage with water significantly reduced MASLD risk by 14.7% (SSBs) and 13.5% (LNSSBs), whereas substitution between LNSSBs and SSBs showed no difference in risk.

“Our study shows that LNSSBs were actually linked to a higher risk of MASLD, even at modest intake levels such as a single can per day,” Liu said.

 “These findings challenge the common perception that these drinks are harmless and highlight the need to reconsider their role in diet and liver health, especially as MASLD emerges as a global health concern.”

Liu, L et al. Sugar- and low/non-sugar-sweetened beverages and risks of metabolic dysfunction-associated steatotic liver disease and liver-related mortality: A prospective analysis of the UK Biobank

Presented at UEG Week 2025; 7 October 2025; Berlin, Germany.

UEG. Artificially sweetened and sugary drinks are both associated with an increased risk of liver disease, study finds. October 7, 2025. Accessed October 7, 2025. 

Heo GY, Koh HB, Park JT, et al. Sweetened Beverage Intake and Incident Chronic Kidney Disease in the UK Biobank Study. 

New research highlights the increased risk of metabolic dysfunction-associated steatotic liver disease (MASLD) and liver-related mortality linked to high consumption of both sugar-sweetened and low- or non-sugar-sweetened beverages. A study involving over 100,000 UK Biobank participants found that consuming more than 330 g/day of these beverages elevates MASLD risk. The study also revealed that replacing these beverages with water significantly reduces MASLD risk. These findings challenge the perception of low- or non-sugar-sweetened beverages as harmless, emphasizing the need for dietary reconsideration.

High intake of both sugar-sweetened beverages and low- or non-sugar-sweetened beverages was linked to greater MASLD risk.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Sugar-, Artificially-Sweetened Beverages Both Linked to Increased MASLD Risk

Director, Center for Lung Analytics and Imaging Research (CLAIR), Endowed Professor of Airways Disease at the University of Alabama at Birmingham School of Medicine

Credit: University of Alabama at Birmingham

Until recently, the treatment landscape of chronic obstructive pulmonary disease (COPD) had few targeted therapies addressing its inflammatory mechanisms, with treatment largely focused on bronchodilators and systemic corticosteroids (SCS). The United States Food and Drug Administration (FDA) approval of Sanofi and Regeneron's 

, under the name Dupixent, in 2024 represented the first biologic option for patients with COPD and evidence of type 2 inflammation—a subset of patients prone to frequent exacerbations and progressive lung function decline.

Data on dupilumab's benefit for COPD continue to be generated, with some of the latest findings coming out of the 2025 European Respiratory Society (ERS) Congress. In an interview with 

, Surya P. Bhatt, MD, professor of medicine in the Division of Pulmonary, Allergy, and Critical Care Medicine at the University of Alabama at Birmingham, discussed new analyses from the pivotal BOREAS and NOTUS trials, which continue to define dupilumab’s clinical impact in COPD driven by type 2 inflammation.

The new ERS data build on that foundation, highlighting dupilumab’s ability to meaningfully reduce the risk of severe exacerbations, emergency department (ED) visits, and SCS use over 52 weeks compared to placebo. These findings reinforce the biologic’s potential not just to modify disease course but to alleviate the clinical and economic burden tied to COPD flare-ups.

In the conversation, Bhatt emphasized that clinically meaningful reductions, including 39% in time-to-first severe exacerbation and 45% in time-to-first severe exacerbation or emergency department visit, further validate dupilumab’s role in improving long-term outcomes. He also discussed how the data strengthen confidence in reducing dependence on systemic corticosteroids, a major goal in managing older, comorbidity-burdened COPD populations.

Were there any notable or surprising findings from the analysis that you’d like to highlight?

This is the first analysis to show dupilumab significantly (nominal 

= .0160) reduced the risk of severe exacerbations compared to placebo. As severe exacerbations in COPD are known to increase healthcare resource utilization, morbidity and mortality risk, these data further demonstrate the ability of dupilumab reduce a key clinical measure of disease that can have broader impacts for patients.

How do these findings build upon the primary outcomes already reported in BOREAS and NOTUS?

These findings are in line with our expectations based on the primary analyses of BOREAS and NOTUS, which demonstrated dupilumab significantly reduced moderate or severe exacerbations and improved lung function compared to placebo. In addition to the risk reduction related to severe exacerbations, this new analysis also emphasizes the ability of dupilumab to reduce other disease impacts that add to a patients overall burden, such as emergency department visits and systemic corticosteroid use.

How significant were the reductions in severe exacerbations and ED visits, and what does this mean for clinical practice?

At 52 weeks, dupilumab significantly reduced risk of the time-to-first severe exacerbation event by 39% (nominal 

= .0160) and the risk of time-to-first severe exacerbation event and/or ED visit by 45% (nominal 

= .0010). Additionally, dupilumab also significantly reduced overall severe exacerbation rates and/or ED visits (nominal 

= .0121). These results emphasize the ability of dupilumab to not only reduce disease burden, but also healthcare resource utilization.

What did the data show about systemic corticosteroid use, and how might dupilumab change the way clinicians rely on SCS for exacerbation management?

The data demonstrate that in patients who had at least one severe exacerbation, dupilumab resulted in significantly fewer days (nominal 

= .0126) requiring systemic corticosteroid use compared to placebo. The results give clinicians confidence that using dupilumab for eligible patients can reduce the need for systemic corticosteroids, treatments that can add to a patient’s overall burden because they are associated with safety risks when used long term.

Given the known safety concerns with chronic SCS use, how meaningful is it that dupilumab both reduced exacerbations and lowered cumulative steroid exposure?

Lowering systemic corticosteroid is particularly important in patients with COPD, who tend to be older, making them more vulnerable to the immunosuppressive impacts of these medicines. Systemic corticosteroid reduction along with severe exacerbation reduction emphasizes the ability of dupilumab to reduce a key clinical outcome and the need for additional treatments, which, together, reduce disease and treatment burden for patients.

From your perspective, how might these results influence treatment guidelines for patients with COPD and type 2 inflammation moving forward?

Dupilumab is already recommended by GOLD for the treatment of eligible patients with COPD. These results provide a fuller picture of the potential impacts that dupilumab can have on key clinical outcomes and healthcare resource utilization, and they can be captured in future guideline updates as appropriate.

We will continue to conduct subgroup analyses of the pivotal BOREAS and NOTUS trials to further understand its impact on additional clinical outcomes and in patient subgroups of interest.

Transcript has been edited for clarity. Bhatt's disclosures include Nuvaira, Sanofi, and Genentench.

Smith T. FDA Approves Dupilumab (Dupixent) for Treatment of COPD. HCPLive. Article. September 27, 2024. https://www.hcplive.com/view/fda-approves-dupilumab-dupixent-for-treatment-of-copd

Bafadhel M, Bhatt SP, Satia I, et al. Dupilumab Reduces the Risk of Severe Exacerbations in Patients With Chronic Obstructive Pulmonary Disease: Results From BOREAS and NOTUS. Presented at: ERS Congress 2025; September 27-October 1, 2025; Amsterdam, Netherlands. Poster #PA4778

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

ERS 2025 Insights: Dupilumab’s Impact on Severe COPD Exacerbations, with Surya Bhatt, MD

Bryan Williams, MD | Image Credit: UCL News

Baxdrostat has achieved its primary endpoint of a statistically significant reduction in ambulatory 24-hour average systolic blood pressure (SBP) in patients with 

, according to data from the Bax24 phase 3 trial.

Baxdrostat is a potential first-in-class, highly potent and selective oral small molecule from AstraZeneca, designed to inhibit aldosterone synthase. Previous clinical trials have shown baxdrostat’s capacity to significantly lower aldosterone levels without affecting cortisol levels across a wide dose range. The drug is currently under investigation as a monotherapy for hypertension and primary aldosteronism, in combination with dapagliflozin for chronic kidney disease and hypertension, and for the prevention of heart failure (HF) in patients with hypertension.

“The Bax24 results show that a once-daily baxdrostat regimen can deliver highly clinically meaningful reductions in 24-hour systolic blood pressure, including in the morning when people are at greater risk of heart attack and stroke,” Bryan Williams, MD, chair of medicine at University College London and primary investigator for Bax24, said in a statement. “These results are groundbreaking and together with the BaxHTN results mean we have the potential to change our treatment approach for the many patients whose hypertension remains uncontrolled despite current therapies.”

Bax24 is a randomized, double-blind, placebo-controlled, parallel group study, evaluating the effect of baxdrostat versus placebo, administered once a day orally, on the reduction of ambulatory SBP in participants with rHTN. For inclusion, patients had to be ≥18 years old with a mean seated SBP of ≥140 mmHg and <170 mmHg at screening. Additionally, patients needed a stable regimen of ≥3 antihypertensive medications from different therapeutic classes including ≥1 diuretic; beta blockers were not included among antihypertensive medication during this study.

A total of 218 patients were randomly assigned in a 1:1 ratio to either baxdrostat 2mg or placebo over the course of a 12-week double-blind period. The primary efficacy endpoint was change from baseline in ambulatory 24-hour average SBP at week 12. Secondary endpoints included the effect of baxdrostat on change from baseline in ambulatory night-time average SBP at week 12, change from baseline in ambulatory daytime average SBP at week 12, and the number of participants achieving ambulatory 24-hour average SBP of <130 mmHg at week 12 and a nocturnal SBP dipping of >10% at week 12, among others.

Ultimately, investigators found a statistically significant reduction in ambulatory 24-hour SBP versus placebo. Efficacy was also observed throughout the 24-hour period, including early morning, at which point patients with hypertension are at increased cardiovascular risk.

“This second phase 3 trial of baxdrostat shows substantial improvement in blood pressure, which reflects its durable half-life of up to 30 hours and highly selective inhibition of aldosterone synthase,” Sharon Barr, executive vice president of BioPharmaceuticals R&D, said in a statement. “Too many patients today have hypertension that remains hard-to-control throughout the day and night, making them especially vulnerable to cardiac events.”

According to the press release from AstraZeneca, full data from Bax24 will be shared with regulatory authorities and presented in a late-breaking session at the American Heart Association Scientific Sessions in November 2025.

AstraZeneca. Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension. BusinessWire. October 7, 2025. Accessed October 7, 2025. 

https://www.businesswire.com/news/home/20251007514703/en/Baxdrostat-met-the-primary-endpoint-in-Bax24-Phase-III-trial-in-patients-with-resistant-hypertension

AstraZeneca. A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants with Resistant Hypertension (Bax24). ClinicalTrials.gov identifier: NCT06168409. Updated October 3, 2025. Accessed October 7, 2025. 

https://clinicaltrials.gov/study/NCT06168409

Baxdrostat, a novel oral small molecule from AstraZeneca, has demonstrated a significant reduction in ambulatory 24-hour average systolic blood pressure in patients with treatment-resistant hypertension, as shown in the Bax24 phase 3 trial. This trial, a randomized, double-blind, placebo-controlled study, involved 218 patients and confirmed baxdrostat's efficacy throughout the 24-hour period, including early morning when cardiovascular risk is heightened. The drug's selective inhibition of aldosterone synthase and durable half-life contribute to its potential as a transformative treatment for uncontrolled hypertension.

The investigative therapy for treatment-resistant hypertension resulted in a substantial reduction in ambulatory 24-hour average systolic blood pressure versus placebo.

Tim Smith joined the MJH Life Sciences team as an assistant editor for HCPLive in August 2022. He graduated from UC Berkeley with a degree in political science, working in multimedia journalism as a staff writer prior to joining MJH. In his spare time, he enjoys reading, watching TV, listening to podcasts, and rock climbing. You can contact him at 

These data highlight secukinumab’s potential as a treatment to provide enhanced psychological outcomes among those with psoriasis.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Secukinumab Shows Superior Psychological Outcomes to Ixekizumab in Psoriasis

Catch up on FDA decisions, critical trial results, and expert perspectives on endocrinology.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 2 Diabetes

Hormonal Disorders

7 Endocrinology Headlines You Missed in September 2025

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

INO-3107 immunotherapy significantly reduces surgeries for recurrent respiratory papillomatosis.

INO-3107 Immunotherapy Shows Benefit in Recurrent Respiratory Papillomatosis

These new, phase 2 findings on the use of topical bimiralisib suggest positive results among patients with actinic keratosis.

Topical Bimiralisib Shows 92% Clearance Rate for Patients with Actinic Keratosis

The Q3 recap for gastroenterology spotlights key FDA decisions, new AGA gastroparesis guidelines, and other top GI news and research.

Irritable Bowel Syndrome

On the HCPLive irritable bowel syndrome page, resources on the topics of medical news and expert insight into IBS can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBS, IBD, and more.

Q3 2025 Recap: Gastroenterology News and Updates

Read about groundbreaking FDA decisions, exciting new heart failure research, and more.

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

Dyslipidemia

7 Cardiology Headlines You Missed in September 2025

This review explores the safety of oral JAK inhibitors in inflammatory skin conditions, with 43 real-world studies being highlighted.

Alopecia

Real-World Findings on Incidence of Adverse Events Highlighted for JAK Inhibitors

The approval is supported by data from the INTEGUMENT-PED phase 3 trial, the INTEGUMENT-OLE long-term extension study, and a phase 1 pharmacokinetic study.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

FDA Approves Roflumilast (Zoryve) Cream 0.05% for Atopic Dermatitis in Children Aged 2-5 Years

The Q3 recap for hepatology spotlights key FDA news, the withdrawal of OCA for PBC, and notable hepatic research from the past few months.

Cholangitis

cholangitis page, resources on the topics of medical news and expert insight into cholangitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on research, treatment, and drug development in PBC, PSC, and more!

Hepatitis C

Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.

Q3 2025 Recap: Hepatology News and Updates

An audio recap of the top 5 stories in healthcare news from the week of 9/28-10/04.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Latest News

LUCENT-3: Mirikizumab (Omvoh) Shows Sustained Benefit in Ulcerative Colitis Through 4 Years

Q3 2025 Recap: Cardiology News and Updates

Sugar-, Artificially-Sweetened Beverages Both Linked to Increased MASLD Risk

ERS 2025 Insights: Dupilumab’s Impact on Severe COPD Exacerbations, with Surya Bhatt, MD

Bax24: Baxdrostat Achieves Primary Endpoint in Treatment-Resistant Hypertension